3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
33
Thoracic
2
Gastrointestinal
2
Tumor-Agnostic
1
Plasma cell
1
Other solid neoplasm
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Prostatic Neoplasms, Castration-Resistant
1
Melanoma
1
Carcinoma, Small Cell
1
Carcinoma, Non-Small-Cell Lung
1
Anus Neoplasms
1
Interventions
Cisplatin
136
Cetuximab
101
pembrolizumab
83
Radiotherapy
62
Carboplatin
57
Radiotherapy, Intensity-Modulated
54
Fluorouracil
47
Docetaxel
47
Nivolumab
44
Paclitaxel
37
Radiation
21
Erlotinib Hydrochloride
19
durvalumab
18
Platinum
15
Ipilimumab
14
Gemcitabine
13
lenvatinib
12
Drug Therapy
12
Bevacizumab
12
Albumin-Bound Paclitaxel
12
vandetanib
11
Pemetrexed
11
Magnetic Resonance Spectroscopy
11
1,2-diaminocyclohexaneplatinum II citrate
11
Radiosurgery
10
Everolimus
10
tremelimumab
9
epacadostat
9
Surgical Procedures, Operative
9
Sorafenib
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
abiraterone
×
Head & Neck
×
Clear all
NCT05551117
2026-02-09
Tamarack
MacroGenics
Phase 2
Terminated
192 enrolled
20 charts